Under the agreement, GenMark has gained non-exclusively license under PerkinElmer’s microfluidics patent portfolio.

GenMark Diagnostics president and CEO Hany Massarany said completing this agreement strengthens the company’s patent portfolio and provides with maximum flexibility as it expands its menu of multiplex molecular tests and develops new platforms that will deliver superior performance to its customers.

PerkinElmer life sciences and technology president Kevin Hrusovsky said the use of microfluidics for multiplexed molecular testing is a key enabling platform for personalized health research.

GenMark’s automated, multiplex molecular diagnostic testing systems detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment.